Shares of AbbVie Inc (NYSE:ABBV) ended Monday session in green amid volatile trading. The shares closed up +0.72 points or 1.14% at $64.08 with 6.65 million shares getting traded. Post opening the session at $62.98, the shares hit an intraday low of $62.66 and an intraday high of $64.23 and the price vacillated in this range throughout the day. The company has a market cap of $103.22 billion and the numbers of outstanding shares have been calculated to be 1.63 billion shares.
on Sept. 9, 2016 The board of directors of AbbVie Inc. (ABBV) declared a quarterly cash dividend of $0.57 per share.
The cash dividend is payable Nov. 15, 2016 to stockholders of record at the close of business on Oct. 14, 2016.
Since the company’s inception in 2013, AbbVie has increased its dividend by more than 42 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
Shares of Skyline Medical Inc (NASDAQ:SKLN) ended Monday session in red amid volatile trading. The shares closed down -0.002 points or -1.16% at $0.170 with 7.48 million shares getting traded. Post opening the session at $0.18, the shares hit an intraday low of $0.16 and an intraday high of $0.18 and the price vacillated in this range throughout the day. The company has a market cap of $12.82 million and the numbers of outstanding shares have been calculated to be 81.80 million shares.
Skyline Medical Inc (SKLN) on Sept. 08, 2016 announced the appointment of Paul Sweetnam, Ph.D. to the Company’s Medical Advisory Board (MAB). Dr. Sweetnam brings to Skyline’s MAB more than 25 years of executive and entrepreneurial experience in the pharmaceutical and biotechnology industries. In addition, Dr. Sweetnam has established an extensive network of scientific collaborators within academia, the government and industry.
Skyline Medical’s MAB was formed in July 2013 and provides guidance and advice to the Company to support its product development goals. Including Dr. Sweetnam, the MAB has five members.
“We are delighted that a scientist of Dr. Sweetnam’s stature has agreed to join our MAB,” said Dr. Carl Schwartz, chairman and interim chief executive officer of Skyline Medical. “His impressive credentials include a track record of identifying and integrating disruptive technologies such as high-throughput and profile screening into the drug discovery and development process. We are looking forward to being able to leverage Dr. Sweetnam’s capabilities as we explore the use of the STREAMWAY System filter as a method of sample collection for rapid diagnostics and biomarker identification in the operating room.”